- $84.31m
- -$11.33m
- 53
- 46
- 45
- 46
Annual income statement for ImageneBio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 9.19 | 31 | 15.6 | 9.16 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 53.7 | 65.1 | 86.5 | 84.6 | 59 |
| Operating Profit | -44.5 | -34.1 | -70.9 | -75.4 | -59 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -44.3 | -34.1 | -68.8 | -68.3 | -49.1 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -44.3 | -34.1 | -68.8 | -68.2 | -49.2 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -44.3 | -34.1 | -68.8 | -68.2 | -49.2 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -44.3 | -34.1 | -68.8 | -68.2 | -49.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -15.4 | -11.4 | -22.8 | -19.3 | -11.5 |
| Dividends per Share |